# CKD Mineral-Bone Disorder (CKD-MBD): Pathophysiology & Management

## Definition & Scope

**CKD-MBD** is a systemic disorder of mineral homeostasis characterized by: 1. **Abnormalities in calcium, phosphate, PTH, vitamin D metabolism** 2. **Bone disease** (abnormal turnover, mineralization, or volume) 3. **Vascular and soft-tissue calcification**

Present in ~80% of CKD G3b–G5; major driver of cardiovascular mortality in ESRD.

Key Point

**CKD-MBD is NOT just “renal osteodystrophy”** — includes vascular calcification, myocardial calcification, and systemic effects of abnormal mineral metabolism.

------------------------------------------------------------------------

## Pathophysiology: The Phosphate-FGF23-PTH-Vitamin D Axis

### **Phase 1: Early CKD (G3a, eGFR 45–59)**

**Trigger:** Nephron loss → ↓ filtered load of phosphate

**Compensatory response:** 1. **FGF23 ↑↑** (fibroblast growth factor 23) - Secreted by osteoblasts/osteocytes in response to ↓ GFR + ↑ phosphate - **Early marker** of dysregulation; may ↑ before serum PO4 rises - Suppresses PTH, ↑ FGF23-mediated phosphate excretion - Inhibits 1,25-(OH)2 vitamin D (active vitamin D) synthesis

1.  **PTH rises slightly** (phosphate retention drives PTH)
    - ↑ Serum PTH → ↑ phosphate excretion per remaining nephron
    - Net effect: Serum PO4 stays NORMAL for longer
2.  **Serum phosphate remains NORMAL** (~3.5–4.5 mg/dL)

Clinical Pearl

Clinical pearl — Early CKD: FGF23 and PTH may rise while phosphate remains normal. This supports appropriate monitoring and assessment of modifiable factors, not prophylactic phosphate binders.

------------------------------------------------------------------------

### **Phase 2: Moderate-to-Advanced CKD (G3b–G4, eGFR 15–44)**

**Worsening phosphate retention:** - More nephrons lost → even with ↑↑ FGF23, phosphate accumulates - **Serum phosphate begins to rise** (\>4.5 mg/dL)

**PTH escalation:** - Combines effects of: hyperphosphatemia + ↓ 1,25(OH)2 vitamin D (low calcium) + persistent FGF23 - PTH ↑↑↑ (may exceed 100 pg/mL)

**Vitamin D metabolism disrupted:** - **↓ 1,25-(OH)2 vitamin D** (active form) - Normally produced by proximal tubule with FGF23 suppression - FGF23 ↑↑ → ↓↓ 1,25(OH)2D synthesis - ↓ 1,25(OH)2D → ↓ intestinal calcium absorption → ↓ serum Ca → ↑ PTH (vicious cycle)

- **↑ 25-OH vitamin D may be normal** — stored form less affected (but may be low from poor nutrition/sun exposure)

**Result:** Secondary hyperparathyroidism (2° HPT) — PTH elevated due to CKD-induced stimuli

------------------------------------------------------------------------

### **Phase 3: Advanced CKD & ESRD (G5, eGFR \<15)**

**Overt hyperphosphatemia:** PO4 \>5 mg/dL

**Tertiary hyperparathyroidism:** PTH becomes autonomous - Even if phosphate, calcium normalize, PTH remains ↑ (from years of stimulation + parathyroid gland hyperplasia)

Calcification risk: Calcium/phosphate loading and active vascular mineralization contribute to arterial and valvular disease. Assess calcium and phosphate individually with PTH trends; a calcium–phosphate product of 55 is not a universal risk or treatment threshold.

**Bone disease spectrum:** 1. **High-turnover bone disease** (secondary HPT) - Excessive PTH → osteoblast & osteoclast activity ↑ - Rapid remodeling, loss of cortical bone, trabecular preservation 2. **Low-turnover bone disease** (adynamic bone) - Suppressed PTH (over-treatment with vitamin D, calcimimetics) - Minimal bone remodeling → impaired fracture healing 3. **Mixed uremic osteodystrophy** — elements of both

Clinical Warning

**Fragility fractures in dialysis patients are common** and cause significant morbidity/mortality despite good Ca/PO4 control. Paradox: high PTH → high turnover → weak bone.

------------------------------------------------------------------------

## Diagnostic Approach: CKD-MBD Screening

### **When to Start Monitoring**

| Stage | Calcium/phosphate | PTH | Other tests |
|----|----|----|----|
| G1–G2 | According to the clinical question | According to the clinical question | No routine adult CKD-MBD schedule solely from stage |
| G3a–G3b | Every 6–12 months when stable | Baseline and interval according to result and CKD progression | Consider 25-OH vitamin D; assess alkaline phosphatase |
| G4 | Every 3–6 months | Every 6–12 months | Alkaline phosphatase annually, more often with high PTH |
| G5/G5D | Every 1–3 months | Every 3–6 months | Alkaline phosphatase annually; vitamin D when useful |

Shorten intervals for changing values, symptoms, or treatment changes. [KDIGO CKD-MBD guidance](https://kdigo.org/guidelines/ckd-mbd/).

### **Key Lab Parameters**

| Test | Normal | Concern in CKD |
|----|----|----|
| **Serum Ca** | 8.5–10.5 mg/dL | \<8.5 (hypocalcemia) or \>10.5 (risk if PO4 also ↑) |
| **Serum PO4** | 2.5–4.5 mg/dL | Progressively or persistently elevated phosphate prompts treatment assessment; interpret with calcium, PTH, diet, and CKD stage |
| **PTH** | 15–65 pg/mL | No established optimal PTH target in nondialysis G3a–G5; in G5D, approximately 2–9 times the assay upper limit, interpreted with trends |
| **25-OH VitD** | 30–100 ng/mL | \<30 (insufficient); \<20 (deficiency) |
| **Ca-PO4 product** | ~35 | Interpret calcium and phosphate separately; no universal product threshold. |
| **Alkaline phosphatase** | 30–120 U/L | ↑ in high-turnover; ↓ in adynamic |
| **FGF23** | \<100 RU/mL | ↑ (research marker; not routine but predictive) |

Clinical Pearl

**FGF23 as early warning:** Rising FGF23 (\>100 RU/mL) at G3a predicts future progression to secondary HPT and bone disease. Not routine but valuable in research settings.

------------------------------------------------------------------------

## Management Strategy by Stage

### **CKD G3a–G3b (eGFR 30–59)**

**Goal:** Prevent secondary HPT development

1.  **Phosphate restriction**
    - Diet: Review phosphate additives and overall intake with a renal dietitian while preserving adequate nutrition; individualize restriction when phosphate is persistently elevated.
    - **No binders needed yet** if serum PO4 normal
2.  **Vitamin D repletion** (if 25-OH VitD \<30)
    - Ergocalciferol (Vitamin D2) 50,000 IU weekly × 12 weeks, then monthly
    - OR Cholecalciferol (Vitamin D3) 1,000–2,000 IU daily
    - Goal: 25-OH VitD 30–100 ng/mL
3.  **Monitor PTH trend**
    - If PTH rises progressively or remains above the assay limit, assess phosphate intake, phosphate, calcium, and vitamin D. A mild single rise is not an automatic calcitriol indication.
4.  **Calcium neutral approach** — avoid hypercalcemia

------------------------------------------------------------------------

### **CKD G4 (eGFR 15–29)**

**Goal:** Control PTH, phosphate; prevent vascular calcification

1.  Phosphate-lowering treatment: Base initiation on progressively or persistently elevated phosphate, assessed together with calcium and PTH; do not use one phosphate value as an automatic binder order.

    - **Calcium-based:** Calcium carbonate, calcium acetate
      - Pro: Inexpensive, help with acidosis
      - Con: Calcium loading can increase hypercalcemia and calcification risk; restrict calcium-based binder exposure in adults and individualize selection without a calcium–phosphate product cutoff.
    - **Non-calcium:** Sevelamer, lanthanum, sucroferric oxyhydroxide
      - Pro: Don’t ↑ Ca; may ↓ phosphate absorption better
      - Con: Expensive, GI tolerability, multiple daily doses

    Key Point

    **Modern trend:** Avoid calcium-based binders in late CKD; prefer non-calcium agents to minimize Ca load and vascular calcification risk.

2.  **Active vitamin D:** Do not use routinely in adult nondialysis CKD. In G4–G5, reserve consideration for severe, progressive hyperparathyroidism after addressing modifiable factors; individualize dose and monitor calcium/phosphate. A PTH cutoff of 110 or a calcium–phosphate product below 55 is not a treatment rule.

3.  **Calcimimetics:** Principally a G5D PTH-lowering option with calcium monitoring. Do not automatically apply a dialysis regimen to nondialysis G4; specialist selection considers the indication, calcium/phosphate, treatment effects, and product labeling.

4.  Monitoring in G4: Calcium/phosphate generally every 3–6 months and PTH every 6–12 months; assess more often when abnormalities or treatment changes warrant it.

------------------------------------------------------------------------

### CKD G5D (dialysis): distinguish dialysis treatment from G5 not receiving dialysis.

**Goal in G5D:** Evaluate PTH against the assay upper limit and its trajectory; avoid treatment oversuppression while addressing persistently elevated phosphate and calcium loading.

1.  **Dialysis phosphate removal**
    - Depends on GFR, urine output, residual kidney function
    - Phosphate removal varies with delivered dialysis duration/frequency, rebound, intake and residual kidney function; assess adequacy in the individual patient.
2.  **Aggressive phosphate management**
    - Binders with meals: Non-calcium preferred (sevelamer, lanthanum)
    - Dietary PO4 restriction \<1,000 mg/day
    - Avoid high-phosphate foods (colas, processed meats, dairy)
3.  **Dialysis PTH framework:** Approximately 2–9 times the assay upper limit, with substantial directional changes prompting reassessment; no universal 150–300 pg/mL target applies to every assay.
4.  **Calcium balance**
    - Avoid hypercalcemia (Ca \>10 mg/dL)
    - Consider low-Ca dialysate if hypercalcemia
5.  **Bone biopsy** (if unexplained bone pain, fractures, or concern for adynamic bone)
    - Tetracycline labeling → assess turnover, mineralization
    - Guides intensity of therapy

------------------------------------------------------------------------

## Newer Agents (Emerging in CKD G3b–G4)

### **FGF23 Antagonists** (Research phase)

- Direct FGF23 blockade is not established routine treatment for CKD-MBD. Do not extrapolate therapies for hypophosphatemic disorders to CKD phosphate retention.

### **Phosphate Binders (Newer generation)**

- Sucroferric oxyhydroxide is an iron-based phosphate binder administered with meals according to its label; it is not a once-daily regimen.
- Patiromer treats hyperkalemia; it is not a substitute for an indicated phosphate-lowering treatment.

------------------------------------------------------------------------

## Bone Health: Fracture Prevention

### **Screening for Osteoporosis in CKD**

- **DXA/BMD testing:** In G3a–G5D with CKD-MBD or osteoporosis risk factors, obtain BMD testing when the result will affect treatment decisions. DXA does not determine the renal bone-turnover subtype; assess that question separately.
- Combine fracture history, falls risk, relevant biochemistry, and BMD when it will change management; consider specialist bone-turnover assessment when needed.

### **Management**

1.  Exercise and nutrition: Encourage safe weight-bearing activity and adequate nutrition. Protein needs differ between nondialysis CKD and dialysis; individualize with a renal dietitian.
2.  **Calcium balance:** Avoid both hypo- and hypercalcemia
3.  **Vitamin D:** Maintain 25-OH VitD \>30 ng/mL
4.  Antifracture therapy in advanced CKD requires assessment of kidney function, CKD-MBD, likely turnover and the selected drug label; use specialist input rather than a blanket regimen.
5.  **Consider anabolic agents** (PTH analogues) if documented low-turnover bone on biopsy (rare, specialized)

------------------------------------------------------------------------

## Vascular Calcification & Cardiovascular Risk

Clinical Warning

**Coronary artery calcification in ESRD:** Present in 40–80% of dialysis patients; major predictor of CV death (more predictive than Framingham risk).

### **Mechanisms of Vascular Calcification in CKD**

1.  Mineral deposition: Calcium and phosphate loading contribute to vascular mineral deposition, but a product of 55 is not a universal precipitation or treatment threshold.
2.  **Active osteogenic conversion:** Vascular smooth muscle cells transdifferentiate → osteoblast-like → produce mineralization matrix
3.  **Loss of calcification inhibitors:** ↓ Fetuin-A, matrix Gla protein (MGP)
4.  **Oxidative stress & inflammation** from uremia

### **Prevention**

- Treat progressively or persistently elevated phosphate, aiming to lower elevated values toward the normal range while considering calcium and PTH together.
- Use the individual calcium and phosphate values rather than a calcium–phosphate product target.
- Avoid excess calcium supplementation
- Use non-calcium binders
- Manage inflammation (dialysis adequacy)

Clinical Pearl

Clinical pearl: Established vascular calcification identifies high cardiovascular risk. Avoid excessive calcium loading and treat persistent mineral abnormalities; prophylactic binders in normophosphatemic early CKD have not been established to prevent future calcification.

------------------------------------------------------------------------

## Related Resources

- Detailed CKD-MBD Pathophysiology
- CKD Staging & Classification
- Dialysis & Mineral Management
- Post-Transplant Bone Management

------------------------------------------------------------------------

## Self-Test Questions

1.  **50M, GFR 40, serum Ca 8.2, PO4 4.6, PTH 95, 25-OH VitD 28**
    - CKD-MBD stage: Mild 2° HPT (early)
    - Intervention: Vitamin D2 to target \>30; dietary PO4 reduction; recheck PTH Q3 months
    - If PTH continues rising, reassess modifiable factors and the trend; do not reflexively prescribe calcitriol for mild G3b hyperparathyroidism.
2.  **72F, GFR 18, Ca 9.8, PO4 6.2, PTH 450, Ca-PO4 product 61**
    - CKD-MBD stage: Advanced 2° HPT with calcification risk
    - Intervention: Confirm persistent phosphate elevation, review intake and select phosphate-lowering treatment. For G4, consider active vitamin D only for severe, progressive hyperparathyroidism after addressing modifiable factors, with calcium/phosphate monitoring.
    - If hypercalcemia develops, reassess calcium-containing treatments and active vitamin D. Do not automatically add a calcimimetic to a nondialysis G4 regimen.
3.  **Dialysis patient, PTH 120 (LOW)**
    - Risk: Adynamic bone disease (suppressed turnover)
    - Intervention: Reduce vitamin D, consider bone biopsy, hold calcimimetics
    - Goal: Review treatment oversuppression using the assay upper limit and trends, rather than forcing PTH into a universal 150–300 interval.

------------------------------------------------------------------------

*Version 1.0 \| PA/Medical student level \| Updated 2026-02-28*

**References:** [KDIGO 2009 CKD–Mineral and Bone Disorder guideline](https://pubmed.ncbi.nlm.nih.gov/19644521/) (Kidney Int Suppl. 2009;113:S1–S130); [KDIGO 2017 CKD-MBD update](https://pubmed.ncbi.nlm.nih.gov/30675420/).

### Also on this topic

The same subject at other levels of depth.

- **Interactive case:** [CKD-Mineral and Bone Disorder](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/mercy/case5_ckd_mbd.html)
- **Clinical Mastery deep dive:** [CKD Mineral and Bone Disease](https://urinenephrology.org/mastery/ckd-advanced/ckd-mbd.html)


---

[Website version](https://urinenephrology.org/student-resources/ckd/ckd-mbd-student-handout.html) · Markdown synchronized October 3, 2026.